ASND
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Ascendis Pharma A/S (ASND) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A-); its weakest is Revisions (F). The rating has held at C for 6 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C (2.4) | B- (2.9) | A- (3.9) | B- (3.1) | F (0.0) | C (2.5) |
| 2026-11-10 | C- (2.1) | B (3.2) | A- (3.9) | B- (3.0) | F (0.0) | C (2.4) |
| 2026-11-03 | C (2.2) | B- (3.1) | A- (3.9) | B- (3.0) | F (0.0) | C (2.4) |
| 2026-10-27 | C (2.2) | B- (3.1) | A- (4.0) | C+ (2.6) | F (0.0) | C (2.4) |
| 2026-10-20 | C (2.3) | B- (3.0) | A- (4.0) | C (2.5) | F (0.0) | C (2.4) |